DDInter1592 DDInter714
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may lead to a major life threatening interaction when taken with {v} Fedratinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Darolutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may lead to a major life threatening interaction when taken with {v} Fedratinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may lead to a major life threatening interaction when taken with {v} Darolutamide
Darolutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Ribociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Darolutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
CYP3A7-CYP3A51P {u} (Gene) is bound by {v} (Compound) Nelfinavir
Nelfinavir {u} may lead to a major life threatening interaction when taken with {v} Fedratinib
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Gilteritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may lead to a major life threatening interaction when taken with Fedratinib
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) resembles Rifampicin (Compound) and Rifampicin may lead to a major life threatening interaction when taken with Fedratinib
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Rifapentine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Rifapentine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Nelfinavir (Compound) and Nelfinavir may lead to a major life threatening interaction when taken with Fedratinib
Rifapentine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib